Sanofi (NASDAQ:SNY) Holdings Increased by Magnetar Financial LLC

Magnetar Financial LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 104.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,340,317 shares of the company’s stock after acquiring an additional 1,705,148 shares during the quarter. Sanofi makes up approximately 3.8% of Magnetar Financial LLC’s investment portfolio, making the stock its biggest position. Magnetar Financial LLC’s holdings in Sanofi were worth $161,103,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Sunbelt Securities Inc. boosted its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC bought a new position in Sanofi in the 4th quarter worth about $44,000. Finally, Versant Capital Management Inc bought a new position in Sanofi in the 4th quarter worth about $54,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY opened at $58.60 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a market capitalization of $148.72 billion, a P/E ratio of 23.53, a P/E/G ratio of 1.01 and a beta of 0.58. The company’s 50-day simple moving average is $54.22 and its two-hundred day simple moving average is $52.89. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, analysts predict that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SNY. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.